Nanoparticle based tailoring of adjuvant function: The role in vaccine development

Journal of Biomedical Nanotechnology

Volumn 10, Issue 9, 2014, Pages 2317-2331

  Prashant, Chandravilas Keshvan ^a   Kumar, Manoj ^b   Dinda, Amit Kumar ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

Author keywords

Immunology; Liposomes; Nanoparticles; Vaccine delivery; Virosomes

Indexed keywords

ANTIGENS; IMMUNOLOGY; LIPOSOMES; NANOPARTICLES;

ANTIGEN PRESENTATION; ANTIGEN PROCESSING; INFECTIOUS DISEASE; RESEARCH AND DEVELOPMENT; VACCINATION STRATEGY; VACCINE DELIVERY; VACCINE DEVELOPMENT; VIROSOMES;

VACCINES;

IMMUNOLOGICAL ADJUVANT; NANOCARRIER; NANOPARTICLE; VACCINE;

ANTIGEN PRESENTATION; CANCER IMMUNIZATION; CANCER PREVENTION; DRUG DELIVERY SYSTEM; HUMAN; INFECTION; INFECTION PREVENTION; MALIGNANT NEOPLASTIC DISEASE; NANOPHARMACEUTICS; NANOTECHNOLOGY; NONHUMAN; REVIEW; VACCINATION; VACCINE PRODUCTION; ANIMAL; CHEMISTRY; IMMUNOLOGY; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; VACCINATION; VACCINES;

EID: 84904880655     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1991     Document Type: Review

References (179)

1. T. D. Nandedkar, Nanovaccines: Recent developments in vaccination. J. Biosci. 34, 995 (2009).
2. S. A. Plotkin and W. A. Orenstein, (eds.), Vaccines, 6th edn., Saunders Elsevier, Amsterdam, The Netherlands (2011).
3. L. J. Peek, C. R. Middaugh, and C. Berkland, Nanotechnology in vaccine delivery. Adv. Drug Deliv. Rev. 60, 915 (2008).
4. H. F. Stills, Jr., Adjuvants and antibody production: Dispelling the myths associated with Freund's complete and other adjuvants. Ilar J. 46, 280 (2005).
5. A. Tagliabue and R. Rappuoli, Vaccine adjuvants: The dream becomes real. Hum. Vaccin. 4, 347 (2008).
6. V. E. Schijns, Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol. 12, 456 (2000).
7. S. G. Reed, S. Bertholet, R. N. Coler, and M. Friede, New horizons in adjuvants for vaccine development. Trends Immunol. 30, 23 (2009).
8. L. Tomljenovic and C. A. Shaw, Aluminum vaccine adjuvants: Are they safe? Curr. Med. Chem. 18, 2630 (2011).
9. A. C. Rice-Ficht, A. M. Arenas-Gamboa, M. M. Kahl-McDonagh, and T. A. Ficht, Polymeric particles in vaccine delivery. Curr. Opin. Microbiol. 13, 106 (2010).
10. V. Hornung, F. Bauernfeind, A. Halle, E. O. Samstad, H. Kono, K. L. Rock, K. A. Fitzgerald, and E. Latz, Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9, 847 (2008).
11. S. Burgdorf and C. Kurts, Endocytosis mechanisms and the cell biology of antigen presentation. Curr. Opin. Immunol. 20, 89 (2008).
12. M. L. De Temmerman, J. Rejman, J. Demeester, D. J. Irvine, B. Gander, and S. C. De Smedt, Particulate vaccines: On the quest for optimal delivery and immune response. Drug Discov. Today 16, 569 (2011).
13. G. Birrenbach and P. P. Speiser, Polymerized micelles and their use as adjuvants in immunology. J. Pharm. Sci. 65, 1763 (1976).
14. J. Kreuter and P. P. Speiser, New adjuvants on a polymethylmethacrylate base. Infect. Immun. 13, 204 (1976).
15. A. J. Almeida, H. O. Alpar, and M. R. Brown, Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(L-lactic acid) microspheres in rats, rabbits and guinea-pigs. J. Pharm. Pharmacol. 45, 198 (1993).
16. C. Sturesson, P. Artursson, R. Ghaderi, K. Johansen, A. Mirazimi, I. Uhnoo, L. Svensson, A. C. Albertsson, and J. Carlfors, Encapsulation of rotavirus into poly(lactide-co-glycolide) microspheres. J. Control Release 59, 377 (1999).
17. S. Y. Kim, H. J. Doh, M. H. Jang, Y. J. Ha, S. I. Chung, and H. J. Park, Oral immunization with Helicobacter pylori-loaded poly(D,L-lactide-co-glycolide) nanoparticles. Helicobacter 4, 33 (1999).
18. M. A. Benoit, B. Baras, and J. Gillard, Preparation and characterization of protein-loaded poly(epsilon-caprolactone) microparticles for oral vaccine delivery. Int. J. Pharm. 184, 73 (1999).
19. P. Johansen, L. Moon, H. Tamber, H. P. Merkle, B. Gander, and D. Sesardic, Immunogenicity of single-dose diphtheria vaccines based on PLA/PLGA microspheres in guinea pigs. Vaccine 18, 209 (1999).
20. M. A. Conway, L. Madrigal-Estebas, S. McClean, D. J. Brayden, and K. H. Mills, Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: Effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine 19, 1940 (2001).
21. C. Moureau, P. L. Vidal, Y. Bennasser, M. Moynier, Y. Nicaise, M. Aussillous, S. Barthelemy, L. Montagnier, and E. Bahraoui, Characterization of humoral and cellular immune responses in mice induced by immunization with HIV-1 Nef regulatory protein encapsulated in poly(DL-lactide-co-glycolide) microparticles. Mol. Immunol. 38, 607 (2002).
22. A. M. Carcaboso, R. M. Hernandez, M. Igartua, A. R. Gascon, J. E. Rosas, M. E. Patarroyo, and J. L. Pedraz, Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66. Int. J. Pharm., 260, 273 (2003).
23. A. C. Stanley, D. Buxton, E. A. Innes, and J. F. Huntley, Intranasal immunisation with toxoplasma gondii tachyzoite antigen encapsulated into PLG microspheres induces humoral and cell-mediated immunity in sheep. Vaccine 22, 3929 (2004).
24. C. S. Chong, M. Cao, W. W. Wong, K. P. Fischer, W. R. Addison, G. S. Kwon, D. L. Tyrrell, and J. Samuel, Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J. Control Release 102, 85 (2005).
25. H. Shen, A. L. Ackerman, V. Cody, A. Giodini, E. R. Hinson, P. Cresswell, R. L. Edelson, W. M. Saltzman, and D. J. Hanlon, Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 117, 78 (2006).
26. T. Gerelchuluun, Y. H. Lee, Y. R. Lee, S. A. Im, S. Song, J. S. Park, K. Han, K. Kim, and C. K. Lee, Dendritic cells process antigens encapsulated in a biodegradable polymer, poly(D,L-lactide-coglycolide), via an alternate class I MHC processing pathway. Arch. Pharm. Res. 30, 1440 (2007).
27. D. Lu, L. Garcia-Contreras, D. Xu, S. L. Kurtz, J. Liu, M. Braunstein, D. N. McMurray, and A. J. Hickey, Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B. Pharm. Res. 24, 1834 (2007).
28. H. F. Florindo, S. Pandit, L. Lacerda, L. M. Goncalves, H. O. Alpar, and A. J. Almeida, The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-epsilon-caprolactone-based nanoparticles. Biomaterials 30, 879 (2009).
29. K. Fu, D. Pack, A. Klibanov, and R. Langer, Visual evidence of acidic environment within degrading Poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm. Res. 17, 100 (2000).
30. E. C. Lavelle, M. K. Yeh, A. G. Coombes, and S. S. Davis, The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol. Vaccine 17, 512 (1999).
31. M. O. Oyewumi, A. Kumar, and Z. Cui, Nano-microparticles as immune adjuvants: Correlating particle sizes and the resultant immune responses. Expert Rev. Vaccines 9, 1095 (2010).
32. J. Kreuter and I. Haenzel, Mode of action of immunological adjuvants: Some physicochemical factors influencing the effectivity of polyacrylic adjuvants. Infect. Immun. 19, 667 (1978).
33. T. Uchida, S. Goto, and T. P. Foster, Particle size studies for subcutaneous delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation. J. Pharm. Pharmacol. 47, 556 (1995).
34. D. Lemoine, M. Deschuyteneer, F. Hogge, and V. Preat, Intranasal immunization against influenza virus using polymeric particles. J. Biomater. Sci. Polym. Ed. 10, 805 (1999).
35. L. Slobbe, N. Medlicott, E. Lockhart, N. Davies, I. Tucker, M. Razzak, and G. Buchan, A prolonged immune response to antigen delivered in poly (epsilon-caprolactone) microparticles. Immunol. Cell Biol. 81, 185 (2003).
36. S. D. Xiang, A. Scholzen, G. Minigo, C. David, V. Apostolopoulos, P. L. Mottram, and M. Plebanski, Pathogen recognition and development of particulate vaccines: Does size matter?. Methods 40, 1 (2006).
37. M. Murillo, M. J. Grillo, J. Rene, C. M. Marin, M. Barberan, M. M. Goni, J. M. Blasco, J. M. Irache, and C. Gamazo, A Brucella ovis antigenic complex bearing poly-epsilon-caprolactone microparticles confer protection against experimental brucellosis in mice. Vaccine 19, 4099 (2001).
38. J. Singh, S. Pandit, V. W. Bramwell, and H. O. Alpar, Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods 38, 96 (2006).
39. Y. K. Oh, C. V. Harding, and J. A. Swanson, The efficiency of antigen delivery from macrophage phagosomes into cytoplasm for MHC class I-restricted antigen presentation. Vaccine 15, 511 (1997).
40. C. K. Prashant, M. Bhat, S. K. Srivastava, A. Saxena, M. Kumar, A. Singh, M. Samim, F. J. Ahmad, and A. K. Dinda, Fabrication of nanoadjuvant with poly-e-caprolactone (PCL) for developing a single-shot vaccine providing prolonged immunity. Int. J. Nanomedicine 9, 937 (2014).
41. C. Foged, B. Brodin, S. Frokjaer, and A. Sundblad, Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int. J. Pharm. 298, 315 (2005).
42. S. T. Reddy, A. Rehor, H. G. Schmoekel, J. A. Hubbell, and M. A. Swartz, In-vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control Release 112, 26 (2006).
43. V. Manolova, A. Flace, M. Bauer, K. Schwarz, P. Saudan, and M. F. Bachmann, Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38, 1404 (2008).
44. V. Kanchan and A. K. Panda, Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 28, 5344 (2007).
45. N. K. Gupta, P. Tomar, V. Sharma, and V. K. Dixit, Development and characterization of chitosan coated poly-(varepsilon-caprolactone) nanoparticulate system for effective immunization against influenza. Vaccine 29, 9026 (2011).
46. C. Thomas, V. Gupta, and F. Ahsan, Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses. Int. J. Pharm. 379, 41 (2009).
47. J. M. Martinez Gomez, N. Csaba, S. Fischer, A. Sichelstiel, T. M. Kundig, B. Gander, and P. Johansen, Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis. J Control Release 130, 161 (2008).
48. R. Han, J. Zhu, X. Yang, and H. Xu, Surface modification of poly(D,L-lactic-co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells. J. Biomed. Mater. Res. A 96, 142 (2011).
49. S. Jain, K. Khomane, A. K. Jain, and P. Dani, Nanocarriers for transmucosal vaccine delivery. Curr. Nanosci. 7, 160 (2011).
50. O. Borges, A. Cordeiro-da-Silva, S. G. Romeijn, M. Amidi, A. de Sousa, G. Borchard, and H. E. Junginger, Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. J. Control Release 114, 348 (2006).
51. M. Gunbeyaz, A. Faraji, A. Ozkul, N. Purali, and S. Senel, Chitosan based delivery systems for mucosal immunization against bovine herpesvirus 1 (BHV-1). Eur. J. Pharm. Sci. 41, 531 (2010).
52. Y. C. Huang, A. Vieira, K. L. Huang, M. K. Yeh, and C. H. Chiang, Pulmonary inflammation caused by chitosan microparticles. J. Biomed. Mater. Res. A 75, 283 (2005).
53. B. Slutter, S. Bal, C. Keijzer, R. Mallants, N. Hagenaars, I. Que, E. Kaijzel, W. van Eden, P. Augustijns, C. Lowik, J. Bouwstra, F. Broere, and W. Jiskoot, Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: Nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine 28, 6282 (2010).
54. O. Borges, G. Borchard, J. C. Verhoef, A. de Sousa, and H. E. Junginger, Preparation of coated nanoparticles for a new mucosal vaccine delivery system. Int. J. Pharm. 299, 155 (2005).
55. B. Semete, L. I. Booysen, L. Kalombo, J. D. Venter, L. Katata, B. Ramalapa, J. A. Verschoor, and H. Swai, In-vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles. Toxicol. Appl. Pharmacol. 249, 158 (2010).
56. B. Slutter, S. M. Bal, I. Que, E. Kaijzel, C. Lowik, J. Bouwstra, and W. Jiskoot, Antigen-adjuvant nanoconjugates for nasal vaccination: An improvement over the use of nanoparticles? Mol. Pharm. 7, 2207 (2010).
57. S. M. Bal, B. Slutter, R. Verheul, J. A. Bouwstra, and W. Jiskoot, Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: Adjuvant- and site-dependent immunogenicity in mice. Eur. J. Pharm. Sci. 45, 475 (2012).
58. K. E. Broaders, J. A. Cohen, T. T. Beaudette, E. M. Bachelder, and J. M. J. Fréchet, Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy. Proc. Natl. Acad. Sci. USA 106, 5497 (2009).
59. E. M. Bachelder, T. T. Beaudette, K. E. Broaders, J. Dashe, and J. M. Frechet, Acetal-derivatized dextran: An acid-responsive biodegradable material for therapeutic applications. J. Am. Chem. Soc. 130, 10494 (2008).
60. L. Cui, J. A. Cohen, K. E. Broaders, T. T. Beaudette, and J. M. Frechet, Mannosylated dextran nanoparticles: A pH-sensitive system engineered for immunomodulation through mannose targeting. Bioconjug. Chem. 22, 949 (2011).
61. L. Zhao, A. Seth, N. Wibowo, C. X. Zhao, N. Mitter, C. Yu, and A. P. Middelberg, Nanoparticle vaccines. Vaccine 32, 327 (2014).
62. A. G. Allison and G. Gregoriadis, Liposomes as immunological adjuvants. Nature 252, 252 (1974).
63. G. Gregoriadis, (eds.), Liposome Technology. 2nd edn., CRC Press Inc., Boca Raton, FL (1993).
64. G. Gregoriadis, B. McCormack, M. Obrenovic, R. Saffie, B. Zadi, and Y. Perrie, Vaccine entrapment in liposomes. Methods 19, 156 (1999).
65. M. Rao and C. R. Alving, Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. Adv. Drug Deliv. Rev. 41, 171 (2000).
66. V. P. Torchilin, Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4, 145 (2005).
67. P. L. Felgner, T. R. Gadek, M. Holm, R. Roman, H. W. Chan, M. Wenz, J. P. Northrop, G. M. Ringold, and M. Danielsen, Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA 84, 7413 (1987).
68. G. Gregoriadis, Genetic vaccines: Strategies for optimization. Pharm. Res. 15, 661 (1998).
69. V. W. Bramwell and Y. Perrie, Particulate delivery systems for vaccines. Crit. Rev. Ther. Drug Carrier Syst. 22, 151 (2005).
70. M. Henriksen-Lacey, D. Christensen, V. W. Bramwell, T. Lindenstrom, E. M. Agger, P. Andersen, and Y. Perrie, Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. J Control Release 145, 102 (2010).
71. Y. Perrie, P. M. Frederik, and G. Gregoriadis, Liposome-mediated DNA vaccination: The effect of vesicle composition. Vaccine 19, 3301 (2001).
72. Y. Perrie, A. R. Mohammed, D. J. Kirby, S. E. McNeil, and V. W. Bramwell, Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm. 364, 272 (2008).
73. G. Gregoriadis, The immunological adjuvant and vaccine carrier properties of liposomes. J. Drug Target 2, 351 (1994).
74. M. Henriksen-Lacey, V. W. Bramwell, D. Christensen, E. M. Agger, P. Andersen, and Y. Perrie, Liposomes based on dimethyldioctade-cylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J. Control Release 142, 180 (2010).
75. G. Gregoriadis, A. Bacon, W. Caparros-Wanderley, and B. McCormack, role for liposomes in genetic vaccination. Vaccine 20, B1-9 (2002).
76. K. S. Korsholm, E. M. Agger, C. Foged, D. Christensen, J. Dietrich, C. S. Andersen, C. Geisler, and P. Andersen, The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 121, 216 (2007).
77. D. Christensen, K. S. Korsholm, I. Rosenkrands, T. Lindenstrom, P. Andersen, and E. M. Agger, Cationic liposomes as vaccine adjuvants. Expert Rev. Vaccines 6, 785 (2007).
78. K. N. Burger and A. J. Verkleij, Membrane fusion. Experientia 46, 631 (1990).
79. X. Zhou and L. Huang, DNA transfection mediated by cationic liposomes containing lipopolylysine: Characterization and mechanism of action. Biochimica et Biophysica Acta (BBA) - Biomembranes 1189, 195 (1994).
80. C. Lonez, M. Vandenbranden, and J. M. Ruysschaert, Cationic liposomal lipids: From gene carriers to cell signaling. Prog. Lipid Res. 47, 340 (2008).
81. C. Lonez, M. Vandenbranden, and J. M. Ruysschaert, Cationic lipids activate intracellular signaling pathways. Adv. Drug Deliv. Rev. 64, 1749 (2012).
82. T. Tanaka, A. Legat, E. Adam, J. Steuve, J. S. Gatot, M. Vandenbranden, L. Ulianov, C. Lonez, J. M. Ruysschaert, E. Muraille, M. Tuynder, and M. Goldman, A. Jacquet, DiC14-amidine cationic liposomes stimulate myeloid dendritic cells through Toll-like receptor 4. Eur. J. Immunol. 38, 1351 (2008).
83. J. Davidsen, I. Rosenkrands, D. Christensen, A. Vangala, D. Kirby, Y. Perrie, E. M. Agger, and P. Andersen, Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim. Biophys. Acta 1718, 22 (2005).
84. A. Vangala, D. Kirby, I. Rosenkrands, E. M. Agger, P. Andersen, and Y. Perrie, A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: Characterisation, environmental scanning electron microscopy and immunisation studies in mice. J. Pharm. Pharmacol. 58, 787 (2006).
85. D. Christensen, K. S. Korsholm, P. Andersen, and E. M. Agger, Cationic liposomes as vaccine adjuvants. Expert Rev. Vaccines 10, 513 (2011).
86. G. Gregoriadis, R. Saffie, and J. B. de Souza, Liposome-mediated DNA vaccination. FEBS Lett. 402, 107 (1997).
87. R. A. Schwendener, B. Ludewig, A. Cerny, and O. Engler, Liposome-based vaccines. Methods Mol. Biol. 605, 163 (2010).
88. D. Christensen, M. Henriksen-Lacey, A. T. Kamath, T. Lindenstrom, K. S. Korsholm, J. P. Christensen, A. F. Rochat, P. H. Lambert, P. Andersen, C. A. Siegrist, Y. Perrie, and E. M. Agger, A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog. J. Control Release 160, 468 (2012).
89. R. Bei, V. Guptill, L. Masuelli, S. V. Kashmiri, R. Muraro, L. Frati, J. Schlom, and J. Kantor, The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice. J. Immunother. 21, 159 (1998).
90. Y. Perrie, S. McNeil, and A. Vangala, Liposome-mediated DNA immunisation via the subcutaneous route. J. Drug Target 11, 555 (2003).
91. S. Shrivastava, K. S. Lole, A. S. Tripathy, U. S. Shaligram, and V. A. Arankalle, Development of candidate combination vaccine for hepatitis E and hepatitis B: A liposome encapsulation approach. Vaccine 27, 6582 (2009).
92. M. Brgles, L. Habjanec, B. Halassy, and J. Tomasic, Liposome fusogenicity and entrapment efficiency of antigen determine the Th1/Th2 bias of antigen-specific immune response. Vaccine 27, 5435 (2009).
93. W. Yan and L. Huang, The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome. Int. J. Pharm. 368, 56 (2009).
94. S. M. Bal, S. Hortensius, Z. Ding, W. Jiskoot, and J. A. Bouwstra, Co-encapsulation of antigen and toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination. Vaccine 29, 1045 (2011).
95. D. P. Vangasseri, Z. Cui, W. Chen, D. A. Hokey, L. D. Falo, Jr., and L. Huang, Immunostimulation of dendritic cells by cationic liposomes. Mol. Membr. Biol. 23, 385 (2006).
96. W. Yan, W. Chen, and L. Huang, Mechanism of adjuvant activity of cationic liposome: Phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol. Immunol. 44, 3672 (2007).
97. J. Y. Cheng, H. N. Huang, W. C. Tseng, T. L. Li, Y. L. Chan, K. C. Cheng, and C. J. Wu, Transcutaneous immunization by lipoplexpatch based DNA vaccines is effective vaccination against Japanese encephalitis virus infection. J. Control Release 135, 242 (2009).
98. W. Chen, W. Yan, and L. Huang, simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol. Immunother. 57, 517 (2008).
99. W. Yan, W. Chen, and L. Huang, Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. J. Control Release 130, 22 (2008).
100. E. Khazanov, D. Simberg, and Y. Barenholz, Lipoplexes prepared from cationic liposomes and mammalian DNA induce CpG-independent, direct cytotoxic effects in cell cultures and in mice. J. Gene Med. 8, 998 (2006).
101. M. M. Whitmore, S. Li, L. Falo, Jr., and L. Huang, Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunol. Immunother. 50, 503 (2001).
102. S. Zhou, S. Kawakami, F. Yamashita, and M. Hashida, Intranasal administration of CpG DNA lipoplex prevents pulmonary metastasis in mice. Cancer Lett. 287, 75 (2010).
103. P. Andersen, Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect. Immun. 62, 2536 (1994).
104. E. R. Brandt, T. Teh, W. A. Relf, R. I. Hobb, and M. F. Good, Protective and nonprotective epitopes from amino termini of M proteins from Australian aboriginal isolates and reference strains of group A streptococci. Infect. Immun. 68, 6587 (2000).
105. L. Holten-Andersen, T. M. Doherty, K. S. Korsholm, and P. Andersen, Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect. Immun. 72, 1608 (2004).
106. M. Henriksen-Lacey, D. Christensen, V. W. Bramwell, T. Lindenstrom, E. M. Agger, P. Andersen, and Y. Perrie, Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3beta-[N-(N′,N′-Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): Prolonged liposome retention mediates stronger Th1 responses. Mol. Pharm. 8, 153 (2011).
107. R. Kaur, V. W. Bramwell, D. J. Kirby, and Y. Perrie, Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses. J. Control Release 158, 72 (2012).
108. R. Kaur, V. W. Bramwell, D. J. Kirby, and Y. Perrie, Manipulation of the surface pegylation in combination with reduced vesicle size of cationic liposomal adjuvants modifies their clearance kinetics from the injection site, and the rate and type of T cell response. J. Control Release 164, 331 (2012).
109. Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers, http://clinicaltrials.gov/ct2/show/ NCT00922363 (2012).
110. D. Christensen, C. Foged, I. Rosenkrands, C. V. Lundberg, P. Andersen, E. M. Agger, and H. M. Nielsen, CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. Int. J. Pharm. 390, 19 (2010).
111. T. Lindenstrom, E. M. Agger, K. S. Korsholm, P. A. Darrah, C. Aagaard, R. A. Seder, I. Rosenkrands, and P. Andersen, Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J. Immunol. 182, 8047 (2009).
112. E. M. Agger, I. Rosenkrands, J. Hansen, K. Brahimi, B. S. Vandahl, C. Aagaard, K. Werninghaus, C. Kirschning, R. Lang, D. Christensen, M. Theisen, F. Follmann, and P. Andersen, Cationic liposomes formulated with synthetic mycobacterial cord-factor (CAF01): A versatile adjuvant for vaccines with different immunological requirements. PLoS One 3, e3116 (2008).
113. A. W. Olsen, M. Theisen, D. Christensen, F. Follmann, and P. Andersen, Protection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model. PLoS One 5, e10768 (2010).
114. H. Yu, X. Jiang, C. Shen, K. P. Karunakaran, J. Jiang, N. L. Rosin, and R. C. Brunham, Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4 + T cells. Infect. Immun. 78, 2272 (2010).
115. I. Rosenkrands, C. Vingsbo-Lundberg, T. J. Bundgaard, T. Lindenstrom, V. Enouf, S. van der Werf, P. Andersen, and E. M. Agger, Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes. Vaccine 29, 6283 (2011).
116. HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease (HIV-BIS), http://clinicaltrials.gov/ct2/show/NCT01141205 (2013).
117. C. S. Andersen, E. M. Agger, I. Rosenkrands, J. M. Gomes, V. Bhowruth, K. J. Gibson, R. V. Petersen, D. E. Minnikin, G. S. Besra, and P. Andersen, A simple mycobacterial monomycolated glycerol lipid has potent immunostimulatory activity. J. Immunol. 182, 424 (2009).
118. S. Igarashi, Y. Hattori, and Y. Maitani, Biosurfactant MEL-A enhances cellular association and gene transfection by cationic liposome. J. Control Release 112, 362 (2006).
119. Y. Maitani, S. Igarashi, M. Sato, and Y. Hattori, Cationic liposome (DC-Chol/DOPE = 1:2) and a modified ethanol injection method to prepare liposomes, increased gene expression. Int. J. Pharm. 342, 33 (2007).
120. Y. Zhang, H. Li, J. Sun, J. Gao, W. Liu, B. Li, Y. Guo, and J. Chen, DC-Chol/DOPE cationic liposomes: A comparative study of the influence factors on plasmid pDNA and siRNA gene delivery. Int. J. Pharm. 390, 198 (2010).
121. B. Guy, N. Pascal, A. Francon, A. Bonnin, S. Gimenez, E. Lafay-Vialon, E. Trannoy, and J. Haensler, Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine 19, 1794 (2001).
122. V. Sanchez, S. Gimenez, J. Haensler, C. Geoffroy, B. Rokbi, D. Seguin, L. Lissolo, B. Harris, F. Rizvi, H. Kleanthous, T. Monath, M. Cadoz, and B. Guy, Formulations of single or multiple H. pylori antigens with DC Chol adjuvant induce protection by the systemic route in mice. Optimal prophylactic combinations are different from therapeutic ones. FEMS Immunol. Med. Microbiol. 30, 157 (2001).
123. A. Vangala, V. W. Bramwell, S. McNeil, D. Christensen, E. M. Agger, and Y. Perrie, Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. J. Control Release 119, 102 (2007).
124. Study of HIV-1 Rgp-160 Administered by Mucosal Routes in Healthy Volunteers, http://clinicaltrials.gov/ct2/show/NCT00122564 (2005).
125. S. W. Dow, L. G. Fradkin, D. H. Liggitt, A. P. Willson, T. D. Heath, and T. A. Potter, Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J. Immunol. 163, 1552 (1999).
126. B. D. Freimark, H. P. Blezinger, V. J. Florack, J. L. Nordstrom, S. D. Long, D. S. Deshpande, S. Nochumson, and K. L. Petrak, Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: Cationic lipid complexes. J. Immunol. 160, 4580 (1998).
127. M. Whitmore, S. Li, and L. Huang, LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther. 6, 1867 (1999).
128. K. Zaks, M. Jordan, A. Guth, K. Sellins, R. Kedl, A. Izzo, C. Bosio, and S. Dow, Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol. 176, 7335 (2006).
129. P. J. Cote, S. D. Butler, A. L. George, J. Fairman, J. L. Gerin, B. C. Tennant, and S. Menne, Rapid immunity to vaccination with woodchuck hepatitis virus surface antigen using cationic liposome-DNA complexes as adjuvant. J. Med. Virol. 81, 1760 (2009).
130. M. Lay, B. Callejo, S. Chang, D. K. Hong, D. B. Lewis, T. D. Carroll, S. Matzinger, L. Fritts, C. J. Miller, J. F. Warner, L. Liang, and J. Fairman, Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine 27, 3811 (2009).
131. S. Chang, J. Warner, L. Liang, and J. Fairman, A novel vaccine adjuvant for recombinant flu antigens. Biologicals 37, 141 (2009).
132. B. B. Gowen, J. Fairman, S. Dow, R. Troyer, M. H. Wong, K. H. Jung, P. C. Melby, and J. D. Morrey, Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: Importance of liposomal delivery and CpG motifs. Antiviral Res. 81, 37 (2009).
133. D. I. Bernstein, N. Farley, F. J. Bravo, J. Earwood, M. McNeal, J. Fairman, and R. Cardin, The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. Vaccine 28, 3748 (2010).
134. Safety, Tolerability and Immunogenicity of Fluzone®With and Without JVRS-100 in Elderly Subjects, http://clinicaltrials.gov/ct2/show/NCT00936468? term=JVRS-00936100+adjuvant&rank=00936462 (2011).
135. L. A. Dykman, M. V. Sumaroka, S. A. Staroverov, I. S. Zaitseva, and V. A. Bogatyrev, Immunogenic Properties of Colloidal Gold. Biology Bulletin 31, 75 (2004).
136. L. A. Dykman, S. A. Staroverov, V. A. Bogatyrev, and S. Yu Shchyogolev, Gold Nanoparticles as an Antigen Carrier and an Adjuvant, Nova Science Publishers, New York (2010).
137. S. A. Staroverov, N. M. Aksinenko, K. P. Gabalov, O. A. Vasilenko, I. V. Vidyasheva, S. Y. Shchyogolev, and L. A. Dykman, Effect of gold nanoparticles on the respiratory activity of peritoneal macrophages. Gold Bull. 42, 153 (2009).
138. D. V. Pow and D. K. Crook, Extremely high titre polyclonal antisera against small neurotransmitter molecules: Rapid production, characterisation and use in light- and electron-microscopic immunocytochemistry. J. Neurosci. Methods 48, 51 (1993).
139. D. Chen and L. G. Payne, Targeting epidermal Langerhans cells by epidermal powder immunization. Cell Res. 12, 97 (2002).
140. D. Chen, C. Zuleger, Q. Chu, Y. F. Maa, J. Osorio, and L. G. Payne, Epidermal powder immunization with a recombinant HIV gp120 targets langerhans cells and induces enhanced immune responses. AIDS Research and Human Retroviruses 18, 715 (2002).
141. D. M. Massich, D. A. Giljohann, D. S. Seferos, L. E. Ludlow, C. M. Horvath, and C. A. Mirkin, Regulating immune response using polyvalent nucleic acid-gold nanoparticle conjugates. Mol. Pharma. 6, 1934 (2009).
142. V. V. Sumbayev, I. M. Yasinska, C. P. Garcia, D. Gilliland, G. S. Lall, B. F. Gibbs, D. R. Bonsall, L. Varani, F. Rossi, and L. Calzolai, Gold nanoparticles downregulate interleukin-1 β-induced pro-inflammatory responses. small 9, 472 (2013).
143. H. Vallhov, J. Qin, S. M. Johansson, N. Ahlborg, M. A. Muhammed, A. Scheynius, and S. Gabrielsson, The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications. Nano Letter 6, 1682 (2006).
144. C. Villiers, H. Freitas, R. Couderc, M.-B. Villiers, and P. Marche, Analysis of the toxicity of gold nano particles on the immune system: Effect on dendritic cell functions. J. Nanoparticle Res. 12, 55 (2010).
145. B. S. Zolnik, A. González-Fernández, N. Sadrieh, and M. A. Dobrovolskaia, Nanoparticles and the immune system. Endocrinology 151, 458 (2010).
146. N. G. Bastús, E. Sánchez-Tilló, S. Pujals, C. Farrera, M. J. Kogan, E. Giralt, A. Celada, J. Lloberas, and V. Puntes, Peptides conjugated to gold nanoparticles induce macrophage activation. Mol. Immunol. 46, 743 (2009).
147. N. G. Bastús, E. Sánchez-Tilló, S. Pujals, C. Farrera, C. López, E. Giralt, A. Celada, J. Lloberas, and V. Puntes, Homogeneous conjugation of peptides onto gold nanoparticles enhances macrophage response. ACS Nano 3, 1335 (2009).
148. M. A. Dobrovolskaia and S. E. McNeil, Immunological properties of engineered nanomaterials. Nat. Nanotechnol. 2, 469 (2007).
149. A. França, P. Aggarwal, E. V. Barsov, S. V. Kozlov, M. A. Dobrovolskaia, and Á. González-Fernández, Macrophage scavenger receptor A mediates the uptake of gold colloids by macrophages In-Vitro, Nanomedicine 6, 1175 (2011).
150. J. S. Ma, W. J. Kim, J. J. Kim, T. J. Kim, S. K. Ye, M. D. Song, H. Kang, D. W. Kim, W. K. Moon, and L. K. H., Gold nanoparticles attenuate LPS-induced NO production through the inhibition of NF-kappaB and IFN-beta/STAT1 pathways in RAW264.7 cells. Nitric Oxide23, 214 (2010).
151. H. J. Yen, S. H. Hsu, and C. L. Tsai, Cytotoxicity and immunological response of gold and silver nanoparticles of different sizes. Small 5, 1553 (2009).
152. Y. S. Chen, Y. C. Hung, W. H. Lin, G. S. Huang, Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide. Nanotechnology 21, 195101 (2010).
153. A. E. Gregory, E. D. Williamson, J. L. Prior, W. Butcher, I. J. Thompson, A. M. Shaw, and R. W. Titball, Conjugation of Y. pestis F1-antigen to gold nanoparticles improves immunogenicity. Vaccine 30, 6777 (2012).
154. M. Kumar, G. Singh, V. Arora, S. Mewar, U. Sharma, N. R. Jagannathan, S. Sapra, A. K. Dinda, S. Kharbanda, and H. Singh, Cellular interaction of folic acid conjugated superparamagnetic iron oxide nanoparticles and its use as contrast agent for targeted magnetic imaging of tumor cells. Int. J. Nanomedicine 7, 3503 (2012).
155. Y. Xu, H. Tang, J. H. Liu, H. Wang, and Y. Liu, Evaluation of the adjuvant effect of silver nanoparticles both in vitro and in vivo, Toxicol. Lett. 219, 42 (2013).
156. S. Bose and S. Tarafder, Calcium phosphate ceramic systems in growth factor and drug delivery for bone tissue engineering: A review. Acta Biomater. 8, 1401 (2012).
157. V. Uskokovic and D. P. Uskokovic, Nanosized hydroxyapatite and other calcium phosphates: Chemistry of formation and application as drug and gene delivery agents. J. Biomed. Mater. Res. B Appl. Biomater. 96, 152 (2011).
158. V. Sokolova, T. Knuschke, J. Buer, A. M. Westendorf, and M. Epple, Quantitative determination of the composition of multishell calcium phosphate-oligonucleotide nanoparticles and their application for the activation of dendritic cells. Acta Biomater. 7, 4029 (2011).
159. Q. He, A. R. Mitchell, S. L. Johnson, C. Wagner-Bartak, T. Morcol, and S. J. Bell, Calcium phosphate nanoparticle adjuvant. Clin. Diagn. Lab. Immunol. 7, 899 (2000).
160. Q. He, A. Mitchell, T. Morcol, and S. J. Bell, Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2. Clin. Diagn. Lab. Immunol. 9, 1021 (2002).
161. D. H. Joyappa, C. A. Kumar, N. Banumathi, G. R. Reddy, and V. V. Suryanarayana, Calcium phosphate nanoparticle prepared with foot and mouth disease virus P1-3CD gene construct protects mice and guinea pigs against the challenge virus. Vet. Microbiol. 139, 58 (2009).
162. L. Zhang, F. X. Gu, J. M. Chan, A. Z. Wang, R. S. Langer, and O. C. Farokhzad, Nanoparticles in medicine: Therapeutic applications and developments. Clin. Pharmacol. Ther. 83, 761 (2008).
163. F. Sharif, F. Porta, A. H. Meijer, A. Kros, and M. K. Richardson, Mesoporous silica nanoparticles as a compound delivery system in zebrafish embryos. Int. J. Nanomedicine 7, 1875 (2012).
164. K. Cheng, K. El-Boubbou, and C. C. Landry, Binding of HIV-1 gp120 Glycoprotein to Silica Nanoparticles Modified with CD4 Glycoprotein and CD4 Peptide Fragments. ACS App. Mater.& Interfaces 4, 235 (2011).
165. H. S. Park, C. W. Kim, H. J. Lee, J. H. Choi, S. G. Lee, Y. P. Yun, I. C. Kwon, S. J. Lee, S. Y. Jeong, and S. C. Lee, A mesoporous silica nanoparticle with charge-convertible pore walls for efficient intracellular protein delivery. Nanotechnology 21, 0957 (2010).
166. Y. Zhao, B. G. Trewyn, I. I. Slowing, and V. S. Y. Lin, Mesoporous silica nanoparticle-based double drug delivery system for glucose-responsive controlled release of insulin and cyclic AMP. J. Am. Chem. Soc. 131, 8398 (2009).
167. K. T. Mody, A. Popat, D. Mahony, A. S. Cavallaro, C. Yu, and N. Mitter, Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine delivery. Nanoscale 5, 5167 (2013).
168. L. P. Mercuri, L. V. Carvalho, F. A. Lima, C. Quayle, M. C. A. Fantini, G. S. Tanaka, W. H. Cabrera, M. F. D. Furtado, D. V. Tambourgi, J. D. R. Matos, M. Jaroniec, and O. A. Sant'Anna, Ordered mesoporous silica SBA-15: A new effective adjuvant to induce antibody response. small 2, 254 (2006).
169. L. V. Carvalho, R. D. C. Ruiz, K. Scaramuzzi, E. B. Marengo, J. R. Matos, D. V. Tambourgi, M. C. A. Fantini, and O. A. Sant'Anna, Immunological parameters related to the adjuvant effect of the ordered mesoporous silica SBA-15. Vaccine 28, 7829 (2010).
170. W. Cabrera, O. Ibanez, S. Oliveira, O. Sant'Anna, M. Siqueira, D. Mouton, and G. Biozzi, Evidence for distinct polygenic regulation of antibody responses to some unrelated antigens in lines of mice selected for high or low antibody responses to somatic antigen of Salmonella. Immunogenetics 16, 583 (1982).
171. G. Biozzi, D. Mouton, C. Stiffel, and Y. Bouthillier, Major role of the macrophage in quantitative genetic regulation of immunoresponsiveness and antiinfectious immunity. Adv. Immun., 36, 189 (1984).
172. G. Biozzi, D. Mouton, O. A. Sant'Anna, H. C. Passos, M. Gennari, M. H. Reis, V. C. Ferreira, A. M. Heumann, Y. Bouthillier, O. M. Ibanez, C. Stiffel, and M. Siqueira, Genetics of immunoresponsiveness to natural antigens in the mouse. Curr Top Microbiol Immunol. 85, 31 (1979).
173. M. Gennari, Y. Bouthillier, O. M. Ibanez, V. C. Ferreira, J. C. Mevel, M. H. Reis, R. M. Piatti, O. G. Ribeiro, and G. Biozzi, Effect of silica on the genetic regulation of antibody responsiveness. Ann. Inst. Pasteur Immunol. 138, 359 (1987).
174. T. Wang, H. Jiang, Q. Zhao, S. Wang, M. Zou, and G. Cheng, Enhanced mucosal and systemic immune responses obtained by porous silica nanoparticles used as an oral vaccine adjuvant: Effect of silica architecture on immunological properties. Int. J. Pharm. 436, 351 (2012).
175. N. Lincopan, M. R. Santana, E. Faquim-Mauro, M. H. da Costa, and A. M. Carmona-Ribeiro, Silica-based cationic bilayers as immunoadjuvants. BMC Biotechnol. 9, 1472 (2009).
176. H. C. Guo, X. M. Feng, S. Q. Sun, Y. Q. Wei, D. H. Sun, X. T. Liu, Z. X. Liu, J. X. Luo, and H. Yin, Immunization of mice by hollow mesoporous silica nanoparticles as carriers of porcine circovirus type 2 ORF2 protein. Virol. J. 9, 9 (2012).
177. D. Mahony, A. S. Cavallaro, F. Stahr, T. J. Mahony, S. Z. Qiao, and N. Mitter, Mesoporous silica nanoparticles act as a self-adjuvant for ovalbumin model antigen in mice. small 9, 3138 (2013).
178. R. Friedman, Nano dot technology enters clinical trials. J. Natl. Cancer Inst. 103, 1428 (2011).
179. M. Benezra, O. Penate-Medina, P. B. Zanzonico, D. Schaer, H. Ow, A. Burns, E. DeStanchina, V. Longo, E. Herz, S. Iyer, J. Wolchok, S. M. Larson, U. Wiesner, and M. S. Bradbury, Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J. Clin. Invest. 121, 2768 (2011).